The role of CDK4/6 inhibitors in early breast cancer
by Miguel Gil-Gil, Emilio Alba, Joaquín Gavilá, Juan de la
Haba-Rodríguez, Eva Ciruelos, Pablo Tolosa, Daniele Candini, Antonio
Llombart-Cussac
The Breast: VOLUME 58, P160-169, AUGUST 01, 2021
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
has proven to be a successful strategy in the treatment of advanced hormone
receptor-positive (HR+) and human epidermal growth factor receptor 2-negative
(HER2 -) breast cancer (BC), leading to a strong interest in their possible
role in the treatment of early luminal BC. In this review we collect the most
relevant and recent information on the use of CDK4/6i for the treatment of
early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate
the results of the large phase 3 adjuvant trials recently released, which have
yielded apparently divergent results.
